Fig. 3
From: Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Results from anti-IL13Rα2::PBD ADC cell viability assays in DIPG/GBM cell models. a Cell viability following incubation with anti-IL13Rα2::PBD ADC for four DIPG cell models (DIPG-17, SF-8628, DIPG-6, DIPG-24) and one GBM cell model (CHLA-200). Values in parentheses are IC50 values. b Cell viability of SF-8628 ex ovo xenograft following anti-IL13Rα2::PBD ADC treatment. The value in parentheses is the IC50 value. Dose response points represent minimum n = 7 quail per concentration